spot_img

Blindsight: The Vision-Restoring Chip Gains ‘Breakthrough Device’ Status

Date:

NAIROBI, Kenya- Elon Musk’s Neuralink is making waves once again. The brain-chip startup announced that its experimental vision-restoring implant, dubbed “Blindsight,” has been granted the “breakthrough device” status by the U.S. Food and Drug Administration (FDA). 

This special designation is reserved for medical devices that offer innovative solutions for life-threatening or irreversibly debilitating conditions, paving the way for faster development and review.

According to Musk, the implant aims to restore vision even for those who have completely lost their eyes and optic nerves. That’s right — Neuralink is reaching for the stars with a device that promises to make the impossible possible. 

Though details on when Blindsight will enter human trials remain elusive, the FDA’s breakthrough status certainly accelerates its path towards clinical testing.

Founded by Musk and a team of engineers in 2016, Neuralink is known for its innovative brain-chip interface that fits snugly within the skull. 

The startup is also developing a separate implant designed to allow paralyzed patients to control digital devices with their thoughts alone. This groundbreaking technology could potentially revolutionize how individuals with spinal cord injuries interact with the world around them.

Neuralink’s current clinical trial plans to enroll three patients to evaluate this device over several years. 

In an earlier success story, the second patient implanted with the device has already started using it to play video games and learn 3D design — a peek into a future where technology seamlessly integrates with human intention.

The core of Neuralink’s technology lies in its implantable chip, which processes and transmits neural signals directly to devices like computers and smartphones. 

It’s a sci-fi concept turned reality, aiming to help disabled individuals regain mobility, communication abilities, and now, even sight. 

While Neuralink has yet to announce when Blindsight will undergo human trials, the FDA’s nod signals a promising step forward.

Neuralink’s audacious journey to blend human thought with digital capabilities is gathering momentum. With the FDA’s breakthrough status for Blindsight, the company is one step closer to making vision restoration a reality.

George Ndole
George Ndole
George is an experienced IT and multimedia professional with a passion for teaching and problem-solving. George leverages his keen eye for innovation to create practical solutions and share valuable knowledge through writing and collaboration in various projects. Dedicated to excellence and creativity, he continuously makes a positive impact in the tech industry.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Share post:

Subscribe

spot_imgspot_img

Trending

More like this
Related

Kiambu Senator Mocks Moses Kuria Over Post-Criticizing Government He Advises: “Lia Kabisa Ikutoke”

NAIROBI, Kenya- In the ever-dynamic world of Kenyan politics,...

President Ruto Meets GenZ Activist Kasmuel McOure in Uasin Gishu 

UASIN GISHU, Kenya - Youth activist Kasmuel McOure who...

Kasmuel McOcure: Betrayal or Evolution of a Gen Z Icon?

NAIROBI, Kenya- Kasmuel McOcure, a name once synonymous with...

Pedestrians and Boda Boda Riders Most Affected as Road Crashes Surge During Festive Season

MOMBASA, Kenya - Road fatalities in the country have...